Identifying the angiogenic receptor expression in mantle cell lymphoma patients and murine models

Cancer research · Mantle cell lymphoma

Dual inhibition of FGFR1 and VEGFR2 with lucitanib improves outcomes in mantle cell lymphoma.

Mantle cell lymphoma (MCL) is an aggressive B‑cell non‑Hodgkin lymphoma that relies on microenvironmental cues for growth and survival. Transcriptomic analyses of patient cohorts and a genetically engineered murine model revealed ten upregulated angiogenic genes, including the receptor tyrosine kinases FGFR1, VEGFR1, VEGFR2, and PDGFRB. FGFR1 and VEGFR2 were the most highly expressed and their high expression correlated with poorer overall survival. Treatment with the small‑molecule inhibitor lucitanib, which blocks both FGFR1 and VEGFR2, reduced proliferation and induced apoptosis of MCL cell lines in vitro, impaired endothelial tube formation, and significantly suppressed tumor growth and prolonged survival in multiple murine MCL models. These findings suggest that dual inhibition of FGFR1 and VEGFR2 may be a promising therapeutic strategy for MCL.

Targeting the angiogenic signaling axis FGFR1–VEGFR2 mitigates MCL tumor progression and survival, offering a potential new therapeutic avenue.

Evidence level: Sejtvonalas. Laboratóriumi sejtekben vizsgálták.

Original source

Related signals